Skip to content
  • Home
  • Signal News
  • Biopharma Digest
    • Market Access Intelligence
    • Rare Disease Gene Therapy
    • Oncology
  • Week in Review
    • GLP-1 Competitive Market
    • NeuroMarket Pulse
      • Neurology Regulatory Interactive Calendar
    • Manufacturing Intelligence
  • Contact

Pharminent

 Posted in Regulatory

FDA clears first genetic hearing loss gene therapy

 April 24, 2026

Pharmaphorum

Regeneron’s Otarmeni is the first gene therapy for congenital hearing loss to be cleared by the FDA, and will be made available for free in the US.

RegulatoryGene TherapyRead full story

Post navigation

Cumberland to sell drug portfolio to Apotex for $100m →
← Cumberland to sell drug portfolio to Apotex for $100m

Categories

© 2026 Pharminent. All rights reserved.

Design by ThemesDNA.com